Under the transaction, Boston Scientific will acquire the remaining 65 percent stake in Cryterion that it didn’t already own.
The deal will give Boston Scientific access to both cryothermal and radiofrequency single-shot balloon-based ablation therapies.
Although Cryterion’s technology hasn’t been approved for use in any country, initial clinical trials have shown promise, according to Keegan Harper, president and CEO of Cryterion Medical.
More articles on supply chain:
3 latest FDA approvals
Mercy shares EHR data with J&J to evaluate medical device safety
Influx of medical waste washes up on Florida beach
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
